Healthcare

Summit Therapeutics’ stock has surged 300% due to high expectations for its promising cancer drug, ivonescimab. Ivonescimab demonstrated superior performance to Merck’s Keytruda in treating non-small cell lung cancer. The drug could generate tens of billions in revenue if it competes effectively